Drug Profile
Research programme: protein therapeutics - Five Prime Therapeutics/UCB
Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics
- Developer Five Prime Therapeutics; UCB
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Inflammation
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 28 Mar 2018 No recent reports of development identified for research development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in USA